NCT05466643View on ClinicalTrials.gov

A Study to Investigate the Effect of DWP16001 as add-on Therapy to Drug A in Patients With Type 2 Diabetes Mellitus

PHASE3RecruitingINTERVENTIONAL
Enrollment

240

Participants

Timeline

Start Date

March 17, 2023

Primary Completion Date

September 30, 2024

Study Completion Date

September 30, 2024

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

DWP16001 0.3mg

1 tablet, Orally, Once daily single dose

DRUG

DWP16001 Placebo

1 tablet, Orally, Once daily single dose

Trial Locations (1)

135-710

RECRUITING

Samsung Medical Center, Seoul

Sponsors
All Listed Sponsors
lead

Daewoong Pharmaceutical Co. LTD.

INDUSTRY